In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Amgen AMGN, and raised the price target from $190.00 to $192.00.
In the report, Deutsche Bank noted, “85.1% of pts in the high-dose arm and 69.2% of pts in the low dose arm achieved PASI75 vs.69.3% of pts in the Stelara arm and 6% on placebo. We note that a significantly greater proportion of pts treated w/ brodalumab achieved clear or almost clear skin by wk 12 vs. Stelara or Placebo according to the Physician Global Assessment (details were not disclosed). AMAGINE-1 showed PASI75 in 83% 210mg treated pts vs 2.7% placebo (in line with AMAGINE-3). The most common AE in the treatment group were common cold, joint pain, upper respiratory infection and headache. Given this and prior safety data we do not see any safety issue.”
Amgen closed on Tuesday at $162.42.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in